Liu Mingsu, Li Guangqin
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Neurobiology, Chongqing, China.
J Stroke Cerebrovasc Dis. 2019 Mar;28(3):531-541. doi: 10.1016/j.jstrokecerebrovasdis.2018.10.007. Epub 2018 Dec 28.
Although endovascular treatment (EVT) is very effective for acute ischemia stroke (AIS) patients with proximal large vessels occlusion (LVO), whether bridging rPA before EVT in stroke patients of LVO is of any benefit and is currently one of the most urgent unanswered questions. We aim to comprehensively determine the efficacy and safety of direct EVT (DEVT) in AIS patients with LVO versus bridging therapy (BT).
Clinical researches published in the Embase, PubMed, and Cochrane Library electronic databases up to May 2017 were identified for analysis. Two reviewers extracted data and conducted quality assessment independently. Statistical tests were performed to check for heterogeneity and publication bias. Subgroup and sensitivity analysis were also conducted to evaluate the robustness of the conclusions.
Overall, 13 studies involving 3302 patients met the inclusion criteria. The AIS patients with DEVT had a similar likelihood to achieve good functional outcome at 3 months (risk ratio [RR] = .93, 95% confidence interval [CI] = .85-1.01, P = .094), mortality at 3 months (RR = 1.10, 95% CI = .91-1.33, P = .33), and symptomatic intracranial hemorrhage (RR = 1.06, 95% CI = .74-1.51, P = .75) versus BT; furthermore, the risk of intracranial hemorrhage was lower in DEVT group (RR = .76, 95% CI = .60-.95, P = .02). No significant difference in recanalization rate existed between the 2 groups (RR = .97, 95% CI = .92-1.02, P = .22); however, in the subgroup analysis, it had a rise trend after DEVT than BT in IVT-eligible group (RR = 1.45, 95% CI = .95-2.22, P = .09).
DEVT appears to have equally effectiveness to BT with a low risk of intracranial hemorrhage in AIS patients with LVO, especially for anterior circulation, which offered a practical information to select appropriate therapeutic strategies for patients with LVO, though the level of evidence seems to be quite shaky.
尽管血管内治疗(EVT)对近端大血管闭塞(LVO)的急性缺血性卒中(AIS)患者非常有效,但在LVO卒中患者中,在EVT前桥接重组组织型纤溶酶原激活剂(rPA)是否有益,是目前最亟待解决的问题之一。我们旨在全面确定直接血管内治疗(DEVT)与桥接治疗(BT)相比,在LVO的AIS患者中的疗效和安全性。
检索截至2017年5月发表在Embase、PubMed和Cochrane图书馆电子数据库中的临床研究进行分析。两名评价者独立提取数据并进行质量评估。进行统计检验以检查异质性和发表偏倚。还进行了亚组分析和敏感性分析以评估结论的稳健性。
总体而言,13项研究共3302例患者符合纳入标准。与BT相比,接受DEVT的AIS患者在3个月时获得良好功能结局的可能性相似(风险比[RR]=0.93,95%置信区间[CI]=0.85-1.01,P=0.094),3个月时的死亡率(RR=1.10,95%CI=0.91-1.33,P=0.33),以及症状性颅内出血(RR=1.06,95%CI=0.74-1.51,P=0.75);此外,DEVT组颅内出血风险较低(RR=0.76,95%CI=0.60-0.95,P=0.02)。两组再通率无显著差异(RR=0.97,95%CI=0.92-1.02,P=0.22);然而,在亚组分析中,在符合静脉溶栓(IVT)条件的组中,DEVT后再通率比BT有上升趋势(RR=1.45,95%CI=0.95-2.22,P=0.09)。
对于LVO的AIS患者,DEVT似乎与BT具有同等疗效,且颅内出血风险较低,尤其是在前循环中,这为LVO患者选择合适的治疗策略提供了实用信息,尽管证据水平似乎相当薄弱。